{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:29:11Z","timestamp":1785929351817,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T00:00:00Z","timestamp":1697932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T00:00:00Z","timestamp":1697932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The most common mode of ovarian cancer (OC) spread is intraperitoneal dissemination, with the peritoneum as the primary site of metastasis. Cytoreductive surgery (CRS) with chemotherapy is the primary treatment. When necessary, a digestive resection can be performed, but the role of mesenteric lymph nodes (MLNs) in advanced OC remains unclear, and its significance in treatment and follow-up evaluation remains to be determined. This study aimed to evaluate the prevalence of MLN involvement in patients who underwent digestive resection for OC peritoneal metastases (PM) and to investigate its potential prognostic value.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective, descriptive study included patients who underwent CRS with curative intent for OC with PM between 1 January 2007 and 31 December 2020. The study assessed MLN status and other clinicopathologic features to determine their prognostic value in relation to overall survival (OS) and progression-free survival (PFS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study enrolled 159 women with advanced OC, 77 (48.4%) of whom had a digestive resection. For 61.1% of the patients who underwent digestive resection, MLNs were examined and found to be positive in 56.8%. No statistically significant associations were found between MLN status and OS (<jats:italic>p<\/jats:italic> = 0.497) or PFS ((<jats:italic>p<\/jats:italic> = 0.659).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In anatomopathologic studies, MLNs are not systematically investigated but are frequently involved. In the current study, no statistically significant associations were found between MLN status and OS or PFS. Further prospective studies with a systematic and standardized approach should be performed to confirm these findings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-023-14405-3","type":"journal-article","created":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T13:01:19Z","timestamp":1697979679000},"page":"605-613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prognostic Impact of Mesenteric Lymph Node Status on Digestive Resection Specimens During Cytoreductive Surgery for Ovarian Peritoneal Metastases"],"prefix":"10.1245","volume":"31","author":[{"given":"Ali","family":"Channawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin-Catalin","family":"Pop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charif","family":"Khaled","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Galdon","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Polastro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Veys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Liberale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,22]]},"reference":[{"key":"14405_CR1","unstructured":"Cancer Fact Sheets, Registre du Cancer, Ann\u00e9e d\u2019incidence 2020, Bruxelles 2022. Retrieved xxxx at https:\/\/kankerregister.org\/media\/docs\/publications\/rapporten\/CancerenBelgique2020(FINAL020822).pdf."},{"issue":"Suppl 1","key":"14405_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","volume":"155","author":"JS Berek","year":"2021","unstructured":"Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021;155(Suppl 1):61\u201385.","journal-title":"Int J Gynaecol Obstet."},{"key":"14405_CR3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","volume":"90","author":"SM Eisenkop","year":"2003","unstructured":"Eisenkop SM, Spirtos NM, Friedman RL, Lin WCM, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90:390\u20136.","journal-title":"Gynecol Oncol."},{"issue":"Suppl","key":"14405_CR4","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1007\/s002800051093","volume":"43","author":"PH Sugarbaker","year":"1999","unstructured":"Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol. 1999;43(Suppl):S15-25.","journal-title":"Cancer Chemother Pharmacol"},{"key":"14405_CR5","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1006\/gyno.1995.0008","volume":"59","author":"KA O\u2019Hanlan","year":"1995","unstructured":"O\u2019Hanlan KA, Kargas S, Schreiber M, et al. Ovarian carcinoma metastases to gastrointestinal tract appear to spread like colon carcinoma: implications for surgical resection. Gynecol Oncol. 1995;59:200\u20136.","journal-title":"Gynecol Oncol"},{"key":"14405_CR6","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1245\/s10434-007-9565-7","volume":"14","author":"R Salani","year":"2007","unstructured":"Salani R, Diaz-Montes T, Giuntoli RL, Bristow RE. Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma. Ann Surg Oncol. 2007;14:3552\u20137.","journal-title":"Ann Surg Oncol"},{"key":"14405_CR7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jso.21940","volume":"104","author":"G Baiocchi","year":"2011","unstructured":"Baiocchi G, Cestari LA, Macedo MP, et al. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection. J Surg Oncol. 2011;104:250\u20134.","journal-title":"J Surg Oncol"},{"key":"14405_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ejso.2011.10.006","volume":"38","author":"S Gouy","year":"2012","unstructured":"Gouy S, Goetgheluck J, Uzan C, Duclos J, Duvillard P, Morice P. Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer. Eur J Surg Oncol. 2012;38:170\u20135.","journal-title":"Eur J Surg Oncol"},{"key":"14405_CR9","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1245\/s10434-014-3558-0","volume":"21","author":"V Gallotta","year":"2014","unstructured":"Gallotta V, Fanfani F, Fagotti A, et al. Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: prognostic role and clinical considerations. Ann Surg Oncol. 2014;21:2369\u201375.","journal-title":"Ann Surg Oncol"},{"key":"14405_CR10","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00404-018-4675-y","volume":"297","author":"R Berretta","year":"2018","unstructured":"Berretta R, Capozzi VA, Sozzi G, et al. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer. Arch Gynecol Obstet. 2018;297:997\u20131004.","journal-title":"Arch Gynecol Obstet"},{"key":"14405_CR11","doi-asserted-by":"publisher","first-page":"7606","DOI":"10.1245\/s10434-021-09899-8","volume":"28","author":"K Tanaka","year":"2021","unstructured":"Tanaka K, Shimada Y, Nishino K, et al. Clinical significance of mesenteric lymph node involvement in the pattern of liver metastasis in patients with ovarian cancer. Ann Surg Oncol. 2021;28:7606\u201313.","journal-title":"Ann Surg Oncol"},{"key":"14405_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4240\/wjgs.v8.i3.179","volume":"8","author":"MLH Ong","year":"2016","unstructured":"Ong MLH, Schofield JB. Assessment of lymph node involvement in colorectal cancer. World J Gastrointest Surg. 2016;8:179\u201392.","journal-title":"World J Gastrointest Surg"},{"key":"14405_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/jnci\/djk092","volume":"99","author":"GJ Chang","year":"2007","unstructured":"Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst. 2007;99:433\u201341.","journal-title":"J Natl Cancer Inst"},{"key":"14405_CR14","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1002\/bjs.10756","volume":"105","author":"KM Marks","year":"2018","unstructured":"Marks KM, West NP, Morris E, Quirke P. Clinicopathological, genomic, and immunological factors in colorectal cancer prognosis. Br J Surg. 2018;105:e99-109.","journal-title":"Br J Surg"},{"key":"14405_CR15","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1093\/annonc\/mdx011","volume":"28","author":"A Karam","year":"2017","unstructured":"Karam A, Ledermann JA, Kim JW, Sehouli J, Lu K, Gourley C, Katsumata N, Burger RA, Nam BH, Bacon M, Ng C, Pfisterer J, Bekkers RLM, Casado Herr\u00e1ez A, Redondo A, Fujiwara H, Gleeson N, Rosengarten O, Scambia G, Zhu J, Okamoto A, Stuart G, Ochiai K. Participants of the 5th ovarian cancer consensus conference. Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: first-line interventions. Ann Oncol. 2017;28:711\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdx011.","journal-title":"Ann Oncol"},{"key":"14405_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ygyno.2012.02.024","volume":"125","author":"SJ Chang","year":"2012","unstructured":"Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining \u201coptimal\u201d residual disease. Gynecol Oncol. 2012;125:483\u201392. https:\/\/doi.org\/10.1016\/j.ygyno.2012.02.024. (Epub 2012 Feb 23).","journal-title":"Gynecol Oncol"},{"key":"14405_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jviscsurg.2019.12.002","volume":"157","author":"G Liberale","year":"2020","unstructured":"Liberale G, Pop CF, Polastro L, et al. A radical approach to achieve complete cytoreductive surgery improve survival of patients with advanced ovarian cancer. J Visc Surg. 2020;157:79\u201386.","journal-title":"J Visc Surg."},{"key":"14405_CR18","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1808424","volume":"380","author":"P Harter","year":"2019","unstructured":"Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380:822\u201332.","journal-title":"N Engl J Med"},{"key":"14405_CR19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/jnci\/dji102","volume":"97","author":"PB Panici","year":"2005","unstructured":"Panici PB, Maggioni A, Hacker N, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst. 2005;97:560\u20136.","journal-title":"J Natl Cancer Inst"},{"key":"14405_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00595-020-02091-7","volume":"51","author":"P Gu","year":"2021","unstructured":"Gu P, Deng J, Sun Z, et al. Superiority of log odds of positive lymph nodes (LODDS) for prognostic prediction after gastric cancer surgery: a multi-institutional analysis of 7620 patients in China. Surg Today. 2021;51:101\u201310.","journal-title":"Surg Today"},{"key":"14405_CR21","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1002\/cncr.24989","volume":"116","author":"Z Sun","year":"2010","unstructured":"Sun Z, Xu Y, Li DM, et al. Log odds of positive lymph nodes. Cancer. 2010;116:2571\u201380.","journal-title":"Cancer"},{"key":"14405_CR22","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.21037\/jgo-21-185","volume":"12","author":"YR Chen","year":"2021","unstructured":"Chen YR, Wang MQ, Li YT, et al. Pronostic performance of different lymph node classification systems in young gastric cancer. J Gastrointest Oncol. 2021;12:1285.","journal-title":"J Gastrointest Oncol"},{"key":"14405_CR23","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s11605-009-0919-2","volume":"13","author":"H Riediger","year":"2009","unstructured":"Riediger H, Keck T, Wellner U, et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg. 2009;13:1337\u201344.","journal-title":"J Gastrointest Surg"},{"key":"14405_CR24","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1245\/s10434-021-11134-3","volume":"29","author":"D Prassas","year":"2022","unstructured":"Prassas D, Kounnamas A, Cupisti K, Schott M, Knoefel WT, Krieg A. Prognostic performance of alternative lymph node classification systems for patients with medullary thyroid cancer: a single-center cohort study. Ann Surg Oncol. 2022;29:2561\u20139.","journal-title":"Ann Surg Oncol"},{"key":"14405_CR25","first-page":"CD005343","volume":"2021","author":"SL Coleridge","year":"2021","unstructured":"Coleridge SL, Bryant A, Kehoe S, Morrison J. Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. 2021;2021:CD005343.","journal-title":"Cochrane Database Syst Rev"},{"key":"14405_CR26","first-page":"169","volume":"25","author":"P Morice","year":"2004","unstructured":"Morice P, Joulie F, Rey A, et al. Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy. Eur J Gynaecol Oncol. 2004;25:169\u201374.","journal-title":"Eur J Gynaecol Oncol"},{"key":"14405_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0003-3944(00)00233-9","volume":"125","author":"C Zinzindohoue","year":"2000","unstructured":"Zinzindohoue C, Lujan R, Boulet S, Spirito C, Bobin JY. Pelvic and para-aortic lymphadenectomy in epithelial ovarian cancer: report of a series of 86 cases. Ann Chir. 2000;125:163\u201372.","journal-title":"Ann Chir"},{"key":"14405_CR28","doi-asserted-by":"publisher","first-page":"334.e1","DOI":"10.1016\/j.ajog.2017.05.036","volume":"217","author":"M Petrillo","year":"2017","unstructured":"Petrillo M, Marchetti C, De Leo R, Musella A, Capoluongo E, Paris I, et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017;217:334.e1-e9.","journal-title":"Am J Obstet Gynecol"},{"key":"14405_CR29","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/jjco\/hyaa124","volume":"50","author":"T Mitamura","year":"2020","unstructured":"Mitamura T, Sekine M, Arai M, Shibata Y, Kato M, Yokoyama S, et al. Risk factors for lymph node metastasis of ovarian, fallopian tube, and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome. Jpn J Clin Oncol. 2020;50:1380\u20135.","journal-title":"Jpn J Clin Oncol"},{"issue":"23","key":"14405_CR30","doi-asserted-by":"publisher","first-page":"00465","DOI":"10.1016\/j.ejso.2023.04.010","volume":"S0748\u20137983","author":"A El Asmar","year":"2023","unstructured":"El Asmar A, Vouche M, Pop F, Polastro L, Chintinne M, Veys I, et al. Deep epigastric lymph nodes implication in patients\u2019 recurrence pattern after cytoreductive surgery in ovarian peritoneal metastases. Eur J Surg Oncol. 2023;S0748\u20137983(23):00465\u20131. https:\/\/doi.org\/10.1016\/j.ejso.2023.04.010.","journal-title":"Eur J Surg Oncol"},{"key":"14405_CR31","doi-asserted-by":"crossref","unstructured":"Khaled, Charif, El Asmar, Antoine, Raisi, Omar, Moreau, Michel, Polastro, Laura, Veys, Isabelle, Pop, Florin C., Donckier, Vincent and Liberale, Gabriel. Prognostic value of preoperative serological biomarkers in patients undergoing cytoreductive surgery for ovarian cancer peritoneal metastases. Pleura Peritoneum. 2023.","DOI":"10.1515\/pp-2022-0199"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14405-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14405-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14405-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T21:38:42Z","timestamp":1701725922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14405-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,22]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["14405"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14405-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,22]]},"assertion":[{"value":"5 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}